Turn Therapeutics Inc.NASDAQ: TTRX

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

· Issued by Turn Therapeutics Inc. via Business Wire

Summary by 6ix AI

Turn Therapeutics Inc., a clinical-stage biotechnology company developing localized therapies for inflammatory skin diseases, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026 at 1:30 PM ET.

Key details

  • CEO Bradley Burnam and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will give the presentation.
  • The presentation will cover the company's atopic dermatitis (eczema) program, including a stage 2 enrichment strategy focused on pruritus (itch) and emerging findings in distinct patient groups.
  • Those groups include patients with moderate-severe itch at baseline and a cohort with lower EASI scores (a measure of eczema extent and severity) despite high disease severity as rated by investigators on the IGA (Investigator's Global Assessment) scale.
  • A live webcast will be available in the Investors section of the Turn Therapeutics website, with a replay available for approximately six months after the presentation.

6ix AI wrote this summary from the release below and checked it against the release.

WESTLAKE VILLAGE, Calif., September 10, 2026--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum as follows:

Date: September 23, 2026
Time: 1:30 PM ET

The presentation will provide a detailed look at the Company's atopic dermatitis clinical program, including its pruritus-focused stage 2 enrichment strategy and emerging findings across distinct patient populations. These include patients with moderate-severe baseline pruritus, as well as a clinically important cohort characterized by lower EASI scores despite high investigator-assessed disease severity (IGA).

A live webcast of the presentation may be accessed on the Investors section of the Turn Therapeutics website at https://ir.turntherapeutics.com/news-events/events. A replay of the webcast will be available on the Turn Therapeutics website for approximately six months following the presentation.

About Turn Therapeutics

Turn Therapeutics Inc. is a clinical-stage biotechnology company developing targeted, non-systemic therapies designed to act directly at the site of disease. The Company's lead therapeutic candidate, GX-03, is being evaluated in atopic dermatitis and is also being developed for onychomycosis. Turn's research focuses on the intersection of microbial activity, local immune signaling and chronic inflammation.

For more information, visit www.turntherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260910567206/en/

Contacts

Investor Relations / Media Contact
Sasha Damouni
Damouni Group LLC
[email protected]

View original source (Business Wire)Turn Therapeutics Inc. on 6ix

Story so far

Earlier from Turn Therapeutics

Later from Turn Therapeutics

All Turn Therapeutics news releases